COMP <GO>
BHC vs LLY // NET PROFIT MARGIN
Bausch Health Companies Inc. (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: BHC 4
— LLY 10
▲ NET PROFIT MARGIN LEADER: LLY
LAST: $8.20 (-7.97%) • MKT CAP: $3.33B
net-margins
1.50%
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
net-margins
31.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BHC VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BHC | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 83.64% | -42.64 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 7.60% | 32.36% | -24.76 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 10.5x | 36.4x | -25.92 | BHC | /valuation <GO> |
| Free Cash Flow Yield | 22.00% | 2.30% | +19.70 | BHC | /fcf-yield <GO> |
| Operating Margin | 17.70% | 40.21% | -22.51 | LLY | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 1.50% | 31.90% | -30.40 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 6.70% | 45.51% | -38.81 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.45 | 9.29 | -8.84 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 9/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 6.77% | +0.03 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 72.3 | 77.9 | -5.58 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.97 | 0.51 | +0.46 | BHC | /macro-sensitivity <GO> |
| Forward P/E Multiple | 19.7x | 26.3x | -6.55 | BHC | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.33B | $1.33T | -$1.33T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BHC REV | LLY REV | BHC GROSS % | LLY GROSS % | BHC FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $10.27B | $65.18B | 44.0% | 83.0% | $1.00B | $16.81B |
| FY 2024 | $9.63B | $45.04B | 44.0% | 81.3% | $1.26B | $8.82B |
| FY 2023 | $8.76B | $34.12B | 44.0% | 79.3% | $637.9M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BHC // BETA 0.97
LLY // BETA 0.51